Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Free Cash Flow of -$30.6 million for Q3 2025, down 43.53% year-over-year from -$54.1 million in Q3 2024, and down 27.66% quarter-over-quarter from -$23.9 million in Q2 2025.
Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$30.6 million for Q3 2025.
- In Q3 2025, Free Cash Flow fell 43.53% year-over-year to -$30.6 million; the TTM figure through Dec 2025 stood at -$82.2 million (down 4.94% YoY), while the FY2024 annual figure was -$78.3 million, down 111.75% from the prior year.
- Free Cash Flow for Q3 2025 stood at -$30.6 million, down from -$23.9 million in the prior quarter.
- The five-year high for Free Cash Flow was $16.4 million in Q3 2022, with the low at -$30.6 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$15.0 million (2024), against an average of -$15.1 million.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow surged 214.9% in 2022, then plunged 206.08% in 2024.
- Dianthus Therapeutics' Free Cash Flow stood at -$15.7 million in 2021, then jumped by 43.46% to -$8.9 million in 2022, then slumped by 33.6% to -$11.9 million in 2023, then plunged by 131.58% to -$27.5 million in 2024, then fell by 11.23% to -$30.6 million in 2025.
- Business Quant data shows DNTH's Free Cash Flow at -$30.6 million in Q3 2025, -$23.9 million in Q2 2025, and -$27.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -30.56 Mn |
| Sep 30, 2025 | -30.56 Mn |
| Jun 30, 2025 | -23.94 Mn |
| Jun 30, 2025 | -23.94 Mn |
| Mar 31, 2025 | -27.65 Mn |
| Mar 31, 2025 | -27.65 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Sep 30, 2024 | -21.29 Mn |
| Sep 30, 2024 | -21.29 Mn |
| Jun 30, 2024 | -14.55 Mn |
| Jun 30, 2024 | -14.55 Mn |
| Mar 31, 2024 | -14.97 Mn |
| Mar 31, 2024 | -14.97 Mn |
| Dec 31, 2023 | -11.86 Mn |
| Dec 31, 2023 | -11.86 Mn |
| Sep 30, 2023 | -10.06 Mn |
| Sep 30, 2023 | -10.06 Mn |
| Jun 30, 2023 | -4.75 Mn |
| Jun 30, 2023 | -4.75 Mn |